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Abstract
Background: A double blind, randomized, placebo controlled study to evaluate the safety and efficacy of the naturally 
derived topical oil, "Neuragen PN®" for the treatment of neuropathic pain.
Methods: Sixty participants with plantar cutaneous (foot sole) pain due to all cause peripheral neuropathy were 
recruited from the community. Each subject was randomly assigned to receive one of two treatments (Neuragen PN® 
or placebo) per week in a crossover design. The primary outcome measure was acute spontaneous pain level as 
reported on a visual analog scale.
Results: There was an overall pain reduction for both treatments from pre to post application. As compared to the 
placebo, Neuragen PN® led to significantly (p < .05) greater pain reduction. Fifty six of sixty subjects (93.3%) receiving 
Neuragen PN® reported pain reduction within 30 minutes. This reduction within 30 minutes occurred in only twenty 
one of sixty (35.0%) subjects receiving the placebo. In a break out analysis of the diabetic only subgroup, 94% of 
subjects in the Neuragen PN® group achieved pain reduction within 30 minutes vs 11.0% of the placebo group. No 
adverse events were observed.
Conclusions: This randomized, placebo controlled, clinical trial with crossover design revealed that the naturally 
derived oil, Neuragen PN®, provided significant relief from neuropathic pain in an all cause neuropathy group. 
Participants with diabetes within this group experienced similar pain relief.
Trial registration: ISRCTN registered: ISRCTN13226601
Background
The incidence of peripheral neuropathy is growing along-
side the epidemic of type 1 and type 2 diabetes [1]. Use of
prescription medication to manage this condition is often
limited to analgesics that can be associated with long
term dependency and side effects, making these less
desirable treatments from a patient's standpoint [2].
Current pharmaceutical treatments of neuropathic pain
include anticonvulsants, antidepressants and opioids. For
example, the American Society of Pain Educators has
released Consensus Treatment Guidelines for the man-
agement of diabetic peripheral neuropathy (DPN) pain. A
board of 11 pain specialists has published the recommen-
dations in a three-tier fashion in the Proceedings of the
Mayo Clinic [3]. The first tier group of drugs to treat DPN
includes duloxetine, oxycodone, pregabalin, and the tri-
cyclic antidepressants. Duloxetine and Pregabalin are oral
prescription medications approved by the FDA to treat
peripheral neuropathic pain [4]. Duloxetine has a myriad
of adverse side effects such as dose dependent blood
pressure increases and multiple drug interactions [5].
Relatively common side effects of pregabalin include diz-
ziness, dry mouth, and coordination problems. The sec-
ond tier drugs include the anticonvulsants
carbamazepine and gabapentin. These drugs are also
associated with a variety of side effects including marked
sedation, dizziness, and dry mouth. It is therefore impor-
tant to consider novel approaches to treating neuropathic
pain that may have less potential side effects.
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Neuragen PN® is an FDA registered homeopathic drug
containing a blend of six homeopathic substances and
five plant based essential oils. The six homeopathic sub-
stances are St. John's Wort (Hypericum perforatum),
Wolfsbane (Aconitum napellus), Club Moss (Lycopodium
clavatum), phosphorus, Poison Ivy (Rhus toxicodendron)
and Rye ergot (Secale cornutum). Their potencies are all
12C, and all six of these substances have a record of tradi-
tional use for nerve related pain (Homeopathic reperato-
ries list them as moderately or strongly recommended
for: Generalities, Injuries, nerves; Generalities, Pain,
burning or shooting) [6]. Although homeopathic sub-
stances are often delivered as single agents (i.e. one sub-
stance per dose), there are a number of clinical studies
that have employed a combination of homeopathic sub-
stances within one product (i.e. multiple substances per
dose) for various disorders [7-10]. Research has also
shown that terpenes and sequiterpenes (found in plant
based essential oils) can enhance skin permeation. The
five essential oils in Neuragen PN®, a proprietary blend of
geranium oil (Pelargonium graveolens), lavender oil
(Lavandula angustifolia), bergamot oil (Citrus auran-
tium), tea tree oil (Melaleuca alternifolia) and eucalyptus
oil (Eucalyptus globulus), act as transdermal carriers.
These carriers are believed to assist in the penetration of
the homeopathic ingredients through the stratum cor-
neum of the skin [11,12].
This study was conducted in the Department of Kinesi-
ology at Louisiana State University (LSU) over a two week
period during the spring of 2008 to examine the analgesic
effects and safety of Neuragen PN®.
Methods
Participants
Individuals with physician diagnosed peripheral neurop-
athy and pain levels greater than 3 but no higher than 8
(on a 0-10 visual analog scale, VAS, of present pain inten-
sity) were recruited through existing University data-
bases, community support groups, and advertisements
placed in community newsletters and newspapers. People
with a pain level greater than 8 were excluded based on
our pilot study which revealed that subjects had difficulty
distinguishing between pain levels of 9 and 10. Pain at
level 10 is labelled as "Worst possible pain", which often is
a state insensitive to actual pain reduction. Potential par-
ticipants were screened according to predetermined
inclusion and exclusion criteria (Table 1). Prior to partici-
pation, eligible participants read and signed an informed
consent form. The project was approved by the Lousiana
State University Institutional Review Board.
Pain Assessment
Self reported pain was assessed by the Short Form McGill
Pain Questionnaire [13]. Present Pain Intensity (PPI) was
reported on a 10 cm Visual Analog Scale (VAS) ranging
from "No Pain" to "Severe Pain." Participant instructions
were to "Mark the line at the point related to the severity
of pain you are currently experiencing in your feet." VAS
scores were calculated by determining the distance
between the left hand side of the scale (i.e., No Pain) and
the mark. Distances were rounded to the nearest centi-
meter to produce a score from 0-10. Numerical rating
scales have been widely used in pain research and have
been demonstrated to be capable of identifying clinically
meaningful changes [14].
Protocol
Participants completed two experimental sessions sepa-
rated by one week. Previous experience indicated that the
clinical effects of Neuragen® typically last approximately 8
hrs and not more than 24 hrs. A one week "washout" was
therefore determined to be an adequate period of time to
minimize carryover effects. Upon arriving at the LSU lab,
p a r t i c i p a n t s  r e c e i v e d  1 0  m i n u t e s  o f  s e a t e d  r e s t  b e f o r e
completing the Short Form McGill Pain Questionnaire
(Pre-Treatment). One of two treatments (described
Table 1: Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
At least 21 years of age. Pregnancy.
Established diagnosis of 
neuropathic pain for at least 
the past 3 months, confirmed 
by primary care physician 
and/or neurologist.
Previous use, continuing use, 
or other knowledge of 
Neuragen PN®.
Pain of at least level 3 and no 
higher than 8 on a 0-10 scale, 
despite other treatments.
Evidence of other types of 
pain as, or more severe, than 
the pain under study.
Normal cognitive and 
communication skills (as 
judged by investigator) and 
ability to complete self report 
questionnaires.
Major psychological 
conditions requiring 
treatment.
History of eczema/atopy/
anaphylaxis or unusual skin 
reactions.
Self reported sensitivity to 
perfumes, essential oils, or 
strong odors.
Changes to current pain 
management regime within 
the previous month.Li BMC Complementary and Alternative Medicine 2010, 10:22
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below) was then given according to a balanced design,
which was performed by the blinded investigator. This
design ensured that all participants would receive both
treatments by the end of the investigation. Half of the
subjects would receive the active treatment first and the
other half would receive the placebo treatment first. Fol-
lowing 30 minutes of additional seated rest (post-treat-
ment), PPI was reassessed using the McGill
questionnaire.
Participants then returned to their normal daily activi-
ties, but were first outfitted with a personal digital assis-
tant (PDA) preprogrammed with the Purdue Momentary
Assessment Tool (PMAT, Bangstate, Inc.). This software
enabled digital presentation of the McGill questionnaire
at specific time points throughout the day. At each time
point, an audio reminder prompted the participant to
answer the questions using the standard PDA touch
screen format. At each time point, the participant was
given a 5 minute window to begin answering the ques-
tionnaire. If the participants did not start answering the
questions within this window, it was disabled until the
next time point. This procedure ensured that participant
responses were given at specific times from initial pain
assessment (2, 3, 4, 5, 6, 7, 8 and 9 hours).
Participant responses were stored on the PDA and
uploaded to a computer during each participant's subse-
quent visit. For each time point the VAS score was calcu-
lated. It is of note that due to screen size limitations, the
digitally presented VAS was shorter than that of the VAS
on paper. The software divided its VAS (~ 4 cm) into ten
equal units, and participant responses were determined
using similar methods to those of the paper version.
At each testing session, participants were given an
adverse event report form and instructed to fill it out to
the best of their ability if they experienced any abnormal
reaction to the treatment.
Treatment
Treatments in the study consisted of two topical oils:
"Neuragen PN®", a topical oil containing homeopathic and
plant extract ingredients, and a placebo consisting of USP
light mineral oil with 5% v/v cis rose oxide added to
approximate the odor of the active treatment. Research-
ers and participants were blinded to treatment, as each
was labeled only as "Neuragen A" or "Neuragen B". The
treatments were labeled by the manufacturer, who in turn
did not reveal the nature of the Neuragen A or B designa-
tions to the investigators until after the data had been
analyzed. Treatments were applied by the researcher to
the skin of the participant's feet. The oil was administered
from a spray bottle with each spray covering the area with
a thin film. One spray was applied to the top of the foot
aimed at the base of the toes, another spray to the top of
the foot half way between the toes and the ankle, one
spray to the internal side of the foot aimed at the middle,
one spray to the external side of the foot aimed at the
middle, and one spray to the underside of the foot aimed
at the ball of the foot. The total amount sprayed was
approximately 0.75 ml per foot per treatment.
Neuragen PN® has a unique floral odor due to its volatile
botanical constituents. It was not possible to replicate the
odor of Neuragen PN® exactly in the placebo without rep-
licating its analgesic effects. However, since participants
were treated only in a clinical setting, the investigator
masked the odors of the treatments by distributing (e.g.
spraying) Neuragen PN® in the treatment room before
application. With the floral odor permeating the room,
investigators and subjects could not distinguish which
treatment they were giving or receiving. This methodol-
ogy also controlled for any potential mechanism of action
involving the effects of fragrance inhalation without topi-
cal application to the skin, since all participants were
exposed to an approximately equivalent level of odor.
Also, any participants with previous knowledge of Neura-
gen PN® were excluded from the study, since they may
have been aware of an association between odor and effi-
cacy.
Statistical Analysis
Test-retest reliability of pre-test Short Form McGill Pain
Questionnaire scores (SPRI, APRI, Total PRI, VAS, and
Overall Intensity of Total Pain Experience) was assessed
by Intraclass Correlation Coefficients (ICC) [15]:
Where   and
; DF -
degree of freedom for error term related to the indepen-
dent variables of "subject", different "test", "repeat" and
the overall "error" term.
Two separate two factor analyses of variance (ANOVA)
with repeated measures were completed to examine the
short term (Pre-treatment and Post-treatment) and long
term (2 - 9 hour) effects of the two treatments. Tukey's
post hoc analysis was employed whenever necessary (P <
.05 observed in main effects or interactions). Significance
level was set at alpha = .05.
Results
Participants
Sixty-seven individuals with physician diagnosed periph-
eral neuropathy were recruited from the community and
ICC
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screened for eligibility. Of these individuals, sixty met all
predetermined inclusion criteria and were included in the
study. All participants completed the intervention in two
different testing sequences in order to balance the poten-
tial order effects (See Figure 1 for details). Participant
demographics, peripheral neuropathy duration and etiol-
ogy, and use of concurrent oral analgesics has been pre-
sented in Table 2.
Effects of Neuragen PN®
All of the items in the McGill Pain Questionnaire
responded similarly to the experimental treatments but
the VAS provided the most quantitative assessment. The
VAS was therefore chosen as the representative criterion
measure due to its high test-retest reliability and wide-
spread use in clinical research.
There was no significant order effect observed due to
different testing sequences. The results were pooled and
only treatment effects are reported here. Pain reduction
effects of Neuragen PN® and the placebo were measured
using the VAS 30 minutes before (Pre) and after (Post)
treatment application. The results are shown in Figure 2.
There was no significant difference in pain levels before
the treatment applications. There was an overall pain
reduction, indicated by the VAS, for both treatments
from pre to post application. Further, Neuragen PN® had
significantly greater pain reduction effects than the pla-
cebo (P < .05).
Table 3 summarizes the pain relieving effects of each
treatment based only on Pre and Post test scores. Fifty-six
of sixty subjects (93.3%) receiving Neuragen PN® reported
pain reduction within 30 minutes. This reduction within
30 minutes occurred in only twenty-one of sixty (35.0%)
subjects receiving the placebo. The number of subjects
exhibiting a 30% reduction in pain or greater was 83% of
patients receiving Neuragen PN® vs 22% receiving the pla-
cebo. In addition, 52% of patients receiving Neuragen PN®
achieved a reduction in pain scores of at least 50% com-
pared with 3% of patients receiving the placebo.
Figure 3 shows the pain reduction effects of the two dif-
ferent treatments over a 9 hour period.
Of the 18 participants with diabetes, 94% reported a
reduction in pain within 30 minutes of the application of
Neuragen PN® c o m p a r e d  w i t h  o n l y  1 1 %  o f  t h e  p a r t i c i -
pants receiving the placebo. In a sub group analysis, 78% Figure 1 Trial outline.
Table 2: Trial participants that met the inclusion criteria
Men n = 24
Women n = 36
Age (years) 69 ± 10
Height (cm) 167 ± 9
Body Mass (kg) 83 ± 21
PN duration (years) 7 ± 5
Diabetes induced PN n = 18
Chemotherapy induced PN n = 2
Idiopathic induced PN n = 32
Other causes of PN (ie. 
Trauma)
n = 8
0 Concurrent Analgesics 21
1 Concurrent Analgesic 30
2 Concurrent Analgesics 6
3 Concurrent Analgesics 3
>3 Concurrent Analgesics 0Li BMC Complementary and Alternative Medicine 2010, 10:22
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of the participants with diabetes receiving Neuragen PN®
experienced a reduction of pain scores of at least 30% ver-
sus only 11% of participants with diabetes treated with
the placebo. In addition, a reduction of pain scores of at
least 50% was experienced by 56% of participants with
diabetes receiving Neuragen PN® and only 6% of partici-
pants with diabetes receiving the placebo.
Discussion
A randomized, double blind placebo controlled clinical
trial was conducted to assess the efficacy of the Neuragen
PN®, a topical analgesic formula, in the treatment of neu-
ropathic pain. This topical oil was tested for its ability to
relieve self-reported foot pain as measured by a visual
analog pain scale. Neuragen PN® and the placebo resulted
in reduced self-reported pain in as little as 30 minutes.
Neuragen PN® treatment resulted in pain reduction over
and above that caused by the placebo (p < .05), however
treatment pain reduction was not significantly different
from the placebo between the hours of 5 and 9.
Peripheral neuropathy related pain levels were tracked
for approximately eight hours following application.
Importantly, the use of portable PDAs equipped with the
Purdue Momentary Assessment Tool (PMAT, Bangstate,
Inc.) allowed participants to leave the laboratory and
return to their normal activities of daily living. This
instrumentation also ensured that all  participant
responses were given on an hourly basis following treat-
ment application (within five minutes). Reported pain
levels (2 - 9 hours) therefore reflect those that may occur
under normal, everyday situations. One limitation of the
results is the small number subjects (n = 60). Another
possible limitation is that the presentation of the VAS on
the PDA was smaller than its presentation on the paper
format. The difference on the absolute scale may influ-
ence the subjects' selection of their subjective pain level.
Therefore, comparison of the data collected on paper (ie.
immediate effects VAS (pre and post)) with data collected
from the PDAs (2 - 9 hours) should be done with caution.
I n  a d d i t i o n ,  n o  e f f o r t  w a s  m a d e  t o  a s s e s s  p a i n  r e l i e f
beyond the reporting period mentioned, or to assess the
long term effects of repeated dosing. Future trials are
planned to address these issues.
More than 50% of people who suffer from diabetes have
(or will develop) diabetic peripheral neuropathy [16].
Treatment of diabetic peripheral neuropathy usually con-
sists of a prescription for gabapentanoids, antidepres-
sants, or opioid analgesics. These prescription
medications have all been found to have a limited success
rate and they are also associated with long term use side
effects [2,17]. Although the mechanism of action of
Neuragen PN® is not known at this time, its efficacy and
good safety profile recommend it's use as another option
in the pain management of peripheral neuropathies.
Figure 2 Average pain reduction effects of Neuragen PN® and the 
placebo, represented by the Visual Analog Scale (VAS), are 
graphed with a time (pre/post) axis. The VAS ranged from 0-10. The 
vertical whiskers on each data point represent the standard error about 
that point. Pre/post pain level was measured 30 minutes before/after 
treatment applications. There was no significant difference in pain lev-
els before the treatment applications. There was an overall pain reduc-
tion for both treatments from pre to post application. Further, 
Neuragen PN® had significantly greater pain reduction effects than the 
placebo (p < .05)
Table 3: VAS pain results for Neuragen PN® and the placebo where SE stands for standard error of the mean.
Treatment Time Mean SE
Neuragen PN® Pre 4.7 0.2
Placebo Pre 4.2 0.2
Neuragen PN® Post 2.53 0.2
Placebo Post 3.98 0.2
There was an overall pain reduction for both treatments from pre to post application. Further, Neuragen PN® had significantly greater pain 
reduction effects than the placebo (p < .05)Li BMC Complementary and Alternative Medicine 2010, 10:22
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Conclusion
Other than capsaicin [18,19], no clinical trials were found
in the literature that investigate the pain relieving effect
of naturally derived over the counter topical treatments
for neuropathic pain. The literature does contain studies
of a number of naturally derived compounds, such as
Cannabinoids [20] and Conotoxins from predatory snails
[21] which are currently in prescription drug develop-
ment for the treatment of neuropathic pain. The results
of this Neuragen PN® clinical trial therefore contribute to
the study of pain reduction by expanding the spectrum of
this type of inquiry. We also believe we are the first to use
P D A s  t o  r e c o r d  p a i n  l e v e l s  o n  a n  h o u r l y  b a s i s .  T h i s
method is easy to use, reliable and accurate. The use of
new technology also contributes to the methodology
development of pain management related studies.
This clinical trial revealed that the naturally derived oil,
Neuragen PN®, provided significant relief from neuro-
pathic pain. Pain relief was statistically significant for up
to 8 hours, and the use of Neuragen PN® resulted in 52%
of subjects (vs 3% of the placebo group) receiving a maxi-
mal pain relief of 50% or greater (P < .05) within 30 min-
utes of application. Additionally, 56% of the diabetic
subgroup receiving Neuragen PN® (vs. 6% of participants
with diabetes in the placebo group) experienced a maxi-
mal pain relief of 50% or greater (P < .05) within 30 min-
u t e s  o f  a p p l i c a t i o n .  A s  t h e r e  w e r e  n o  a d v e r s e  e v e n t s
reported during the study period, Neuragen PN® is rec-
ommended as a safe and efficacious treatment to provide
temporary relief from neuropathic pain.
ISRCTN registered: ISRCTN13226601
Competing interests
The study is funded by Origin Biomed Inc. http://originbiomed.com/. Origin
Biomed has participated in study design, decision to publish, and preparation
of the manuscript. However, Origin Biomed did not take part in the data collec-
tion, data analysis, or interpretation and discussion of the results.
Acknowledgements
This study is partially supported by Origin Biomed Inc, Reilly Family Foundation, 
and Louisiana Life Course and Aging Center. Origin Biomed's Chief Scientific 
Officer, Alexander McLellan contributed to the trial design.
Author Details
Department of Kinesiology, Louisiana State University, Baton Rouge, LA 70803, 
USA
References
1. Setacci C, de Donato G, Setacci F, Chisci E: Diabetic patients: 
epidemiology and the global impact.  J Cardiovasc Surg 2009, 
50(3):263-273.
Received: 15 April 2010 Accepted: 20 May 2010 
Published: 20 May 2010
This article is available from: http://www.biomedcentral.com/1472-6882/10/22 © 2010 Li; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Complementary and Alternative Medicine 2010, 10:22
Figure 3 Average pain reduction effects of Neuragen PN® and the placebo, represented by the Visual Analog Scale (VAS) where 0 indicates 
no pain and 10 indicates maximal or severe pain. The vertical whiskers on each data point represent the standard error about that point. Pre pain 
level was measured 30 minutes (hour 0) before treatment application and post pain was measured 30 minutes (hour 1) after treatment application 
and every hour thereafter (hour 2 - 9), up to 8 hours. There was a pain reduction (p < .05) for both treatments up to hour 9. Neuragen PN® led to more 
pain reduction than the pacebo during the first 4 hours after treatment applicationLi BMC Complementary and Alternative Medicine 2010, 10:22
http://www.biomedcentral.com/1472-6882/10/22
Page 7 of 7
2. Attal, N: Drug treatment for neuropathic pain.  Presse Med 2008, 37(2 Pt 
2):346-353.
3. Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE, 
Fishbain DA, Irving GA, McCarberg BH, McLean MJ: Consensus 
guidelines: treatment planning and options.  Mayo Clinic Proceedings 
2006, 81(4):S12-S25.
4. O'Connor AB: Neuropathic pain: quality-of-life impact, costs and cost 
effectiveness of therapy.  Pharmacoeconomics 2009, 27(2):95-112.
5. Duloxetine: new indication. Depression and diabetic neuropathy: too 
many adverse effects.  Prescrire Int 2006, 15(85):168-172.
6. Kent JT: Repertory of the homeopathic materia medica 6th edition. New 
Delhi: World Homeopathic Links; 1982. 
7. Wiesenauer M, Gaus W, Bohnacker U, Häussler S: Efficiency of 
homeopathic preparation combinations in sinusitis. Results of a 
randomized double blind study with general practitioners.  
Arzneimittelforschung 1989, 39(5):620-625.
8. Jacobs J, Guthrie BL, Montes GA, Jacobs LE, Mickey-Colman N, Wilson AR, 
DiGiacomo R: Homeopathic combination remedy in the treatment of 
acute childhood diarrhea in Honduras.  J Altern Complement Med 2006, 
12(8):723-732.
9. Jacobs J, Fernandez EA, Merizalde B, Avila-Montes GA, Crothers D: The use 
of homeopathic combination remedy for dengue fever symptoms: a 
pilot RCT in Honduras.  Homeopathy 2007, 96(1):22-26.
10. Maiwald VL, Weinfurtner T, Mau J, Connert WD: Therapy of common cold 
with a homeopathic combination preparation in comparison with 
acetylsalicylic acid. A controlled, randomized double-blind study.  
Arzneimittelforschung 1988, 38(4):578-582.
11. Ghafourian T, Zandasrar P, Hamishekar H, Nokhodchi A: The effect of 
penetration enhancers on drug delivery through skin: a QSAR study.  J 
Control Release 2004, 99(1):113-125.
12. Nokhodchi A, Sharabiani K, Rashidi MR, Ghafourian T: The effect of 
terpene concentrations on the skin penetration of diclofenac sodium.  
Int J Pharm 2007, 335(1-2):97-105.
13. Melzack R: The short-form McGill Pain Questionnaire.  Pain 1987, 
30(2):191-197.
14. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM: Clinical 
importance of changes in chronic pain intensity measured on an 11-
point numerical pain rating scale.  Pain 2001, 94(2):149-158.
15. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater 
reliability.  Psychol Bull 1979, 2:420-428.
16. Aring AM, Jones DE, Falko JM: Evaluation and prevention of diabetic 
neuropathy.  Am Fam Physician 2005, 71(11):2123-2128.
17. Lynch ME: The pharmacotherapy of chronic pain.  Rheum Dis Clin North 
Am 2008, 34(2):369-385.
18. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Rauck R, Tobias J: 
NGX-4010, a high-concentration capsaicin patch, for the treatment of 
postherpetic neuralgia: a randomized, double-blind study.  Lancet 
Neurology 2008, 7:1106-1112.
19. Hayman M, Kam PCA: Capsaicin: A review of its pharmacology and 
clinical applications.  Current Anaesthesia & Critical Care 2008, 19:338-343.
20. Fontelles MIM, Garcia CG: Role of cannabinoids in the management of 
neuropathic pain.  CNS Drugs 2008, 22(8):645-653.
21. Alonso D, Khalil Z, Satkunanathan N, Livett BG: Drugs from the sea: 
conotoxins as drug leads for neuropathic pain and other neurological 
conditions.  Mini Reviews in Medicinal Chemistry 2003, 3:785-787.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6882/10/22/prepub
doi: 10.1186/1472-6882-10-22
Cite this article as: Li, The effect of Neuragen PN® on Neuropathic pain: A 
randomized, double blind, placebo controlled clinical trial BMC Complemen-
tary and Alternative Medicine 2010, 10:22